Key result
Colchicine shows no benefit over placebo for MACE in recent MI patients.
Why the study?
The role of colchicine in improving cardiovascular outcomes in patients with recent myocardial infarction remained unclear.
Does colchicine reduce major adverse cardiovascular events in patients with recent myocardial infarction?
Does colchicine reduce major adverse cardiovascular events in patients with recent myocardial infarction?
In patients with recent myocardial infarction, colchicine does not conclusively reduce major adverse cardiovascular events compared to placebo over a 1- to 3-year follow-up.
Colchicine does not reduce MACE after recent MI; challenges weak prior consensus for benefit.
Background The role of colchicine, an anti-inflammatory agent, in improving cardiovascular outcomes in patients with recent myocardial infarction (MI) remains unclear. Purpose To compare the rates of major adverse cardiovascular events (MACE) among patients randomized to colchicine versus placebo with recent MI (within 1 month of symptom onset). Methods We systematically searched MEDLINE, Embase, and the Cochrane Library from inception to January 2025 for randomized controlled trials (RCTs) comparing colchicine to placebo in recent MI. The primary outcome was MACE (as defined by the included studies), assessed at maximum follow-up, with a minimum follow-up duration of 1 year. Secondary outcomes included individual MACE components and safety endpoints (serious adverse events [SAEs], any adverse events [AEs], and gastrointestinal AEs). Count data were pooled using random-effects models with inverse variance weighting to obtain risk ratios (RRs) and 95% confidence intervals (CIs). Results A total of five RCTs were included with 6,620 patients randomized to colchicine and 6,625 to placebo. Most participants (79%) were male, with mean ages ranging from 59 to 61 years. Follow-up durations ranged from 1 to 3 years. At maximum follow-up, pooled data for MACE showed wide CIs, with no conclusive evidence of colchicine superiority over placebo (RR 0.83, 95% CI 0.66-1.04). Analyses of individual MACE components (all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, myocardial infarction, stroke, atrial fibrillation, ischemia driven revascularization, and re-hospitalization) were also inconclusive. The RR for AEs (1.00, 95% CI 0.94-1.06) and SAEs (0.95, 95% CI 0.80-1.12) indicated no significant difference in safety outcomes among participants randomized to colchicine or placebo. Subgroup analyses assessed the impact of earlier colchicine initiation (closer to the index event; RR 0.84, 95% CI 0.59-1.18) and prolonged treatment duration (≥1 year; RR 0.81, 95% CI 0.45-1.46) on MACE outcomes, but neither showed a definitive effect. Conclusion In patients with recent MI, the available evidence assessing the effect of colchicine on MACE and safety outcomes remains inconclusive over a median follow-up duration of one year.
No takes yet. Share an insight, caveat, or question.
Moiz et al. (2025) studied this question. Colchicine did not significantly reduce major adverse cardiovascular events (RR 0.83, 95% CI 0.66-1.04) or affect safety outcomes in recent MI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: